Abbott Laboratories has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s ...

Abbott Laboratories is delivering double-digit percentage earnings growth along with a dependable dividend.

In November 2025, Abbott struck an agreement to acquire Exact Sciences for approximately $21 billion. Madison, Wisconsin–based Exact Sciences develops cancer screening and diagnostic tests. Its ...

Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The Medical Devices and Established Pharmaceuticals segments drive high single-digit growth for Abbott. Check out why ABT ...

Abbott ABT has consistently demonstrated strong growth and gained market share within its Nutrition business. Its Diabetes Care business continues to benefit from the growing sales of its flagship, ...

Abbott Laboratories’ ABT Established Pharmaceuticals Division (“EPD”) operates solely in emerging geographies, with leading positions in many of the largest and fastest-growing pharmaceutical markets ...

Abbott Laboratories's (NYSE: ABT) short interest as a percent of float has fallen 8.33% since its last report. According to exchange reported data, there are now 17.20 million shares sold short, which ...

复宏汉霖 (02696)发布公告，于2026年2月24日，经双方友好磋商，公司与KGBio订立修订及部分终止协议，以终止原KGBio许可协议项下于除印度尼西亚以外的其他地区 ...